Selection of resistance mutations in pregnant women receiving zidovudine and lamivudine to prevent HIV perinatal transmission

被引：15

作者：

Giuliano, M

Palmisano, L

Galluzzo, CM

Amici, R

Germinario, E

Okong, P

Kituuka, P

Mmirro, F

Magoni, M

Vella, S

机构：

[1] Ist Super Sanita, Virol Lab, I-00161 Rome, Italy

[2] St Francis Nsambya Hosp, Kampala, Uganda

[3] Mulago Hosp, Kampala, Uganda

来源：

AIDS | 2003年 / 17卷 / 10期

关键词：

D O I：

10.1097/00002030-200307040-00022

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Two zidovudine/lamivudine regimens for the prevention of HIV perinatal transmission were studied for the selection of resistance mutations. The M184V mutation was detected one week after delivery in six out of fifty women (12%) who received the regimen prepartum, intrapartum and postpartum, and was no longer present 3 months later. No nucleoside reverse transcriptase inhibitor resistance-associated mutations were detected in 50 women who received zidovudine/lamivudine intrapartum and postpartum only. No association with the risk of perinatal transmission was found.

引用

页码：1570 / 1572

页数：3

共 50 条

[21] Reducing Perinatal HIV Transmission Among HIV-Infected Pregnant Women
Soza-Vento, Rita M.
Flowers, Lakeesha
Munroe, Alelia E.
Fritz, Kathy
Rua-Dobles, Ana
Munroe, Carmel
Singer, Bill
JOINT COMMISSION JOURNAL ON QUALITY AND PATIENT SAFETY, 2007, 33 (04): : 187 - 192
[22] Zidovudine prophylaxis and perinatal HIV-1 transmission
Zuccotti, GV
Ferraris, G
Agostoni, C
Rancilio, L
Ravizza, M
Bucceri, AM
Riva, E
Marini, A
ACTA PAEDIATRICA, 1999, 88 (11) : 1298 - 1298
[23] Detection of HIV drug resistance mutations in pregnant women receiving single dose Nevirapine in south India
Jacob, Mini S.
Durairaj, Anitha
Vijayakumari, James
Srijayanth, Parameshwari
Sivakumar, M. R.
INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY, 2011, 54 (02) : 359 - 361
[24] Incremental cost-effectiveness of two zidovudine regimens to prevent perinatal HIV transmission in the United States
Pinkerton, SD
Holtgrave, DR
Layde, PM
PREVENTIVE MEDICINE, 2000, 30 (01) : 64 - 69
[25] Ethics of placebo-controlled trials of zidovudine to prevent the perinatal transmission of HIV in the Third World - Reply
Lurie, P
Wolfe, SM
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (12): : 840 - 841
[26] Lack of adequate prenatal care is related to poor implementation of zidovudine prophylaxis to prevent perinatal HIV transmission
Wilson, TE
Royce, R
Lampe, M
Ickovics, J
Fernandez, MI
Koenig, L
CLINICAL INFECTIOUS DISEASES, 2001, 33 (07) : 1223 - 1223
[27] Zidovudine resensitization and dual HIV-1 resistance to zidovudine and lamivudine in the Delta lamivudine roll-over study
Masquelier, B
Descamps, D
Carrière, I
Ferchal, F
Collin, G
Denayrolles, M
Ruffault, A
Chanzy, B
Izopet, J
Buffet-Janvresse, C
Schmitt, MP
Race, E
Fleury, HJA
Aboulker, JP
Yeni, P
Brun-Vézinet, F
ANTIVIRAL THERAPY, 1999, 4 (02) : 69 - 77
[28] Etravirine resistance mutations in HIV-infected pregnant women
Cecchini, D. M.
Zapiola, I.
Fernandez Giuliano, S.
Martinez, M. G.
Rodriguez, C. G.
Bouzas, M. B.
HIV MEDICINE, 2013, 14 (02) : 125 - 126
[29] Intermittent selection pressure with zidovudine plus zalcitabine treatment reduces the emergence in vivo of zidovudine resistance HIV mutations
Izopet, J
Sailler, L
Sandres, K
Pasquier, C
Bonnet, E
Aquilina, C
Puel, J
Massip, P
Marchou, B
JOURNAL OF MEDICAL VIROLOGY, 1999, 57 (02) : 163 - 168
[30] Evolution of HIV drug resistance in zidovudine/zalcitabine- and zidovudine/didanosine-experienced patients receiving lamivudine-containing combination therapy
Schmit, JC
Martinez-Picado, J
Ruiz, L
Tural, C
Van Laethem, K
Cabrera, C
Ibanez, A
Puig, T
Witvrouw, M
Desmyter, J
De Clercq, E
Clotet, B
Vandamme, AM
ANTIVIRAL THERAPY, 1998, 3 (02) : 81 - 88

← 1 2 3 4 5 →